Quince Therapeutics (NASDAQ:QNCX) Now Covered by Brookline Capital Management

Stock analysts at Brookline Capital Management began coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm set a “buy” rating and a $9.00 price target on the stock. Brookline Capital Management’s price target points to a potential upside of 389.13% from the stock’s previous close.

Several other equities analysts also recently issued reports on QNCX. EF Hutton Acquisition Co. I upgraded Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 22nd. Maxim Group started coverage on Quince Therapeutics in a research note on Thursday, November 7th. They issued a “buy” rating and a $6.00 price target for the company. Rodman & Renshaw started coverage on shares of Quince Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $11.00 price objective on the stock. Finally, RODMAN&RENSHAW upgraded shares of Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 29th. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $8.67.

Quince Therapeutics Trading Down 3.7 %

Shares of NASDAQ:QNCX opened at $1.84 on Wednesday. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33. The company’s 50-day moving average price is $1.55 and its 200 day moving average price is $1.01. The company has a market cap of $80.96 million, a PE ratio of -1.48 and a beta of 0.74. Quince Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.45.

Institutional Investors Weigh In On Quince Therapeutics

A hedge fund recently raised its stake in Quince Therapeutics stock. Geode Capital Management LLC raised its stake in Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 339,125 shares of the company’s stock after buying an additional 66,170 shares during the period. Geode Capital Management LLC owned approximately 0.78% of Quince Therapeutics worth $263,000 as of its most recent filing with the SEC. 30.75% of the stock is owned by institutional investors and hedge funds.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.